Slovakofarma to be taken over by Leciva?
Press reports in Prague, the Czech Republic, say that local drugmakerLeciva may acquire Slovakia's largest pharmaceutical company, Slovakofarma, according to the CTK news agency's Business News. Negotiations are said to be underway, but it is understood that fellow Czech drugs firm IVAX CR may also be interested in buying the Slovak firm.
Meantime, Slovakofarma has reported a net profit of 180 million koruna ($37.1 million) on sales of 5.44 billion koruna for the first nine months of 2001. While the profit was down 33% year-on-year, turnover increased 24%, the news agency notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze